AEC Partners is proud to have supported EverImmuneNovember 2021
We are proud to have supported EverImmune in its series A funding, enabling its lead product, Oncobax® AK, to enter the clinical stage in microbiota immuno-oncology
AEC Partners is proud to have supported ValbiotisApril 2021
AEC Partners is proud to have supported Valbiotis with its estimated sizing of the mild to moderate hypertension market
AEC Partners supports Biomunex Pharmaceuticals with the signing of its second licensing deal as well as an equity investment in its ongoing series A fundingFebruary 2021
AEC Partners is proud to have supported Biomunex Pharmaceuticals with the signing of its second deal. After its licensing deal with Sanofi in 2019, Biomunex has now entered into a licensing and co-development agreement with Onward Therapeutics for a proprietary bispecific antibody program in hematological malignancies. The deal includes a strategic equity investment in Biomunex's ongoing Series A round.
Plan Compétences Biotech 2025February 2021
AEC Partners est heureux d’avoir été sélectionné par le Leem et l’OPCO2i pour développer le Plan des compétences Biotech à 2025 pour la France.
Cette étude vise à caractériser la position stratégique de la France sur 10 grandes familles de biotechnologie afin de répondre aux besoins en compétences.
AEC Partners is delighted to have been selected by the Leem and OPCO2i * to develop the “France 2025 Biotech Skills Plan”.
The objective of this study is to specify the strategic positioning of France among the 10 main families of biotechnology products, and identify needs to meet the associated skill requirements.
*
LEEM: Les Entreprises du Medicament – Industry Association representing pharma companies operating in France
OPCO2i : Opérateurs de Compétences 2i - Agency financing further education & learning in France
Favoriser le développement de capacités de Bioproduction de biothérapies innovantes sur le territoire Français : Recommandations pour créer un environnement favorable et attractifFebruary 2021
AEC Partners présente ses recommandations pour créer un environnement favorable au développement de capacités de Bioproduction de biothérapies innovantes sur le territoire français.
Commanditée par le Leem, cette étude identifie les 6 points clés liés à la Bioproduction qui obèrent la capacité de la France à accompagner ses acteurs de la filière des biothérapies. Elle propose des recommandations pour créer un écosystème complet, favorable et attractif.
DEVELOPING BIOMANUFACTURING CAPACITIES FOR INNOVATIVE BIOTHERAPIES IN FRANCE: RECOMMENDATIONS FOR CREATING A FAVORABLE AND ATTRACTIVE ENVIRONMENT
AEC Partners presents its recommendations for creating a favorable environment for the development of biomanufacturing capacities for innovative biotherapies in France. Sponsored by the Leem*, this report identifies six key points that impact France’s ability to support biotherapy players and provides recommendations to create an integrated, favorable and attractive ecosystem.
*LEEM: Les Entreprises du Medicament - French pharmaceutical industry professional association
ETUDE SUR L’INTELLIGENCE ARTIFICIELLE DANS LES INDUSTRIES DE SANTÉ : VISION ET BESOINS EN COMPETENCESJanuary 2021
AEC Partners vous présente son étude sur l’Intelligence Artificielle dans les industries de santé.
Commanditée par le Ministère du travail, le Leem, le SNITEM et l’Union, cette étude cerne les enjeux de l’Intelligence Artificielle(IA) en santé en France. Elle établit une cartographie des entreprises impliquées en IA et définit les besoins en compétences et nouveaux métiers sur toute la chaîne de valeur des industries de santé.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE: VISION & REQUIRED SKILLS
AEC Partners presents its study on Artificial Intelligence (AI) in healthcare.
Sponsored by the French Ministry for Employment, Leem, SNITEM and L'UNION, this study identifies the challenges of AI for healthcare in France. It provides a comprehensive mapping of the companies involved in AI, and identifies the impact for healthcare industries in terms of skills and new professions required along their value chain.
*French Industry Associations
LEEM: Les Entreprises du Medicament - representing pharma companies operating in France
SNITEM : Syndicat National de l'Industrie des Technologies Médicales – representing Medical Device and Health Information & Communication Technology companies operating in France
L'UNION: Union des organisations professionnelles et patronales signataires de la convention collective nationale de la fabrication et du commerce des produits à usage pharmaceutique, parapharmaceutique et vétérinaire – representing professional & employer organizations for companies manufacturing & commercializing pharmacy, parapharmacy & veterinary products
Etude sur les Solutions Multi-Technologiques de Santé (SMT)December 2020
AEC Partners vous présente son étude sur les Solutions Multi-Technologiques de Santé.
Commanditée par le Ministère du travail, le Leem, le SNITEM et L’UNION,
cette étude analyse la position concurrentielle de la France sur les Solutions Multi-Technologiques de Santé, élabore des recommandations pour la renforcer, cartographie les métiers et compétences nécessaires et propose un plan d’action de développement.
AEC Partners presents its study on Multi-Technological Health Solutions.
Commissioned by the French Ministry for Employment, Leem*, SNITEM* & L'UNION*, this study analyzes France's competitive positioning in Multi-Technological Health Solutions, develops recommendations to strengthen this position, maps the required roles and skill-sets and proposes a supporting action plan ”
*French Industry Associations
LEEM: Les Entreprises du Medicament - representing pharma companies operating in France
SNITEM : Syndicat National de l'Industrie des Technologies Médicales – representing Medical Device and Health Information & Communication Technology companies operating in France
L'UNION : Union des organisations professionnelles et patronales signataires de la convention collective nationale de la fabrication et du commerce des produits à usage pharmaceutique, parapharmaceutique et vétérinaire – representing professional & employer organizations for companies manufacturing & commercializing pharmacy, parapharmacy & veterinary products
Le groupe Apicil et Equitim annoncent leur rapprochement pour construire ensemble un acteur majeur des produits structuresSeptember 2019
Apicil acquires a majority shareholding of equitim - structured product advisory and brokerage services provider.
Annual meeting of Longwood FundApril 2019
Daniel Teper, our AEC Partner in the US, will participate at the Annual meeting of Longwood Fund (www.longwoodfund.com) at Harvard Medical School in Boston on Tuesday, April 30, 2019.
Longwood is one of the top performing healthcare venture capital funds.Its Managing Partners are co-founders of biotech companies such as Alnylam, Acceleron, Momenta, Sitris and Vertex.
Daniel is a speaker on the Business and Corporate Development panel along with senior pharma executives.
Deal Making Forecast: Paul Biondi, SVP, Head, BD, Bristol-Myers Squibb; Daniel Karp, EVP, Corporate Development, Biogen; Prakash Raman, Global Head, BD&L, Novartis Institutes for Biomedical Research; David Steinberg, Partner, Longwood Fund; Daniel Teper, Chair, Vector Therapeutics and Partner, AEC Partners; Ivana Magovcevic-Liebisch, EVP & CBO, Ipsen
Daniel joined AEC in the fall 2018 to reinforce our strategy consulting and transaction practices in the US. Daniel was the Managing Director North America for Bionest Partners and a Partner at ISO Healthcare (now Deloitte Monitor) in New York. Daniel was previously the Global President for HAVAS EURO RSCG Healthcare. Daniel has held senior positions in the pharmaceutical industry and is a serial entrepreneur in biotech, currently being the Chairman of Vector Therapeutics. Daniel holds a Doctor of Pharmacy (PharmD) degree from Paris XI University and an MBA form INSEAD.
Partnership Valbiotis/AEC PartnersJanuary 2019
AEC Partners announces the signature of a partnership agreement with Valbiotis to support the company with its commercial development strategy // AEC Partners annonce la signature d’un partenariat avec la société Valbiotis pour l’accompagner dans son développement commercial
MergermarketAugust 2018
Apicil remains on the lookout for new acquisition opportunities in Europe, exec says
Communiqué de presseAugust 2018
Apicil acquires OneLife (€5.2bn in assets under management), a European leader in customised asset and wealth management solutions from JC Flowers pending regulatory clearance from the CAA in Luxembourg.
Communiqué de presseJuly 2018
Le consortium composé des Groupes Apicil,OFI, et Crystal est entré en discussions exclusives en vue du rachat de la plateforme FINAVEO & Associés
Etude prospective des organisations et des métiers de l\'informationMay 2018
AEC Partners accompagne le LEEM et donne une vision de l’évolution des organisations et des métiers de l’information auprès des Professionnels de santé, au sein des filiales France.
Si vous souhaitez recevoir l’étude complète, n’hésitez pas à en faire la demande via notre formulaire de contact.
Moreau SAS fait l\'acquisition de la société portugaise TEMAHOME SAJanuary 2018
MOREAU SAS fait l\'acquisition de la société portugaise TEMAHOME SA, conseillée par Stéphane Olmi - AEC Partners
La startup de la finance FundShop lève 2,2 millions d’euros auprès d’ApicilJune 2017
La startup de la finance FundShop lève 2,2 millions d’euros auprès d’Apicil, conseillée par Stéphane Olmi - AEC Fintech
Mrs Garnier appointed as Onxeo board memberApril 2017
Mrs. Christine Garnier, AEC Partners Managing Partner, was appointed as Onxeo board member
ACQUISITION INTERNATIONALApril 2017
AEC Partners was recognized as the Best French Life Sciences M&A Advisory Firm of the Year from the magazine Acquisition International
DécideursMarch 2017
AEC Partners ranked as « Excellent » among Healthcare consultants by Strategy & Finance Business magazine “Décideurs”
BiotechfinancesDecember 2016
Comment les biotech pourront-elles innover demain ?
AEC Partners salue le lancement du Lab SantéDecember 2016
AEC Partners pays tribute to the official launch of Lab Santé/
AEC Partners tient à saluer le lancement officiel du Lab Santé
Etude Biotechs/Innovations Santé 2020November 2016
AEC Partners accompagne le LEEM France et donne une vision de l’évolution des 10 grandes familles de Biotechs/Innovations Santé à 2020
Orange ConsultingApril 2015
AEC Partners and Orange Consulting are uniting their strengths and complementary expertise to address digital opportunities and challenges along the full value chain for life science companies.
APICILFebruary 2015
Groupe APICIL : feu vert pour l’acquisition des activités de Skandia en France
et au Luxembourg auprès d’Old Mutual
Acquisition of Skandia FranceSeptember 2014
Stéphane Olmi, Partner, advised Apicil Assurances on the acquisition of Skandia France, the French life-insurance subsidiary of Old Mutual
ACQUISITION INTERNATIONALJuly 2014
AEC Partners was recognized as the French Healthcare Advisory Firm of the Year 2014, by the magazine Acquisition International
ETUDE PRISME – AEC PARTNERS POUR L’AMIPSApril 2014
Projection sur la Responsabilité des Industries de Santé, leurs métiers Médicaux et leurs Evolutions Télécharger l’étude Lire un article
InvestirOctober 2013
AEC Partners in the press – Investir – Dossier « Un traitement de choc efficace pour les géants de la pharmacie » Read the article
BIOTECH FINANCESSeptember 2013
AEC Partners on the cover page of Biotech Finances «Après les USA, la biotech européenne peut-elle rebondir ?»
Sale of Laserson SASeptember 2013
Stéphane Olmi, Partner at AEC Partners, advised the Laserson family on the sale of Laserson SA to Safic-Alcan
ACQUISITION INTERNATIONALJuly 2013
AEC Partners was recognized as the French Healthcare Advisory Firm of the Year from the magazine Acquisition International. See the M&A Award
DÉCIDEURSJanuary 2013
AEC Partners ranked as « Excellent » among Healthcare consultants by Strategy & Finance Business magazine “Décideurs”
MEDCDTLL édite son avenirJuly 2012
AEC Partners assisted Edmond de Rothschild Investment Partners in assessing Edimark’s strategic outlook. Beyond Edimark’s competitive position and strengths, it was critical to provide a comprehensive understanding of where drug promotion is going in France, and in particular the consequences of complex environmental and regulatory changes on medical and scientific press. We believe that our intimate understanding of the challenges faced by the drug industry comforted Edrip in their investment decision.
Edrip and AEC Partners have been collaborating on a regular basis over the past 3 years. Rodolphe Gobe, Partner at AEC Partners, was in charge of this assignment.
BIOTECH FINANCESMay 2012
Alkantis un pure player medtech…
BIOTECH FINANCESApril 2012
Immunothérapie 2025 : quelles opportunités pour la France ?
DÉCIDEURSJanuary 2012
We are referenced in the Strategy & Finance Publication “Décideurs” in January 2012 among their “Best of” Financial Advisory companies for the Healthcare & Pharmaceutical Industry: Small & Mid Size Cap -
ETUDE POUR LE LEEM SUR L’ÉVOLUTION DES FORCES TERRAINNovember 2011
AEC PARTNERS PARTICIPATION ON THE OECD BIOMARKERS REPORTNovember 2011
BIOTECH FINANCESOctober 2011
Biosimilaires d’anticorps monoclonaux : un avenir incertain ?
AEC Partners advised IPL in selling its Food Control activity to AlpJuly 2011
AEC Partners advised Marceau Conseil in selling one of their activitiesJuly 2011
ETUDE POUR LE LEEM SUR LES MÉTIERS ÉMERGENTSJune 2011